Enanta Pharma (ENTA) Tops Q3 EPS by 4c. Revs Miss

Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($0.44), $0.04 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $7.5 million versus the consensus estimate of $8.14 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Energy Fuels to acquire rare earth magnet maker VAC for $1.9 billion
• BofA lists top 5 themes driving next $1tn in incremental semi sales